🇺🇸

US SEC Filing Intelligence

· daily

USA Insider Trading Pulse — September 09, 2026

Today's 'USA Insider Trading Pulse' is dominated by a massive, coordinated wave of open-market purchases by 27 officers of Taiwan Semiconductor Manufacturing Co. (TSMC) at a uniform $76.20 price point, sending an overwhelmingly bullish signal from the semiconductor powerhouse's executive ranks. This cluster of insider buying, totaling ~$107K across 27 transactions, is the most significant signal across the 50 filings and strongly suggests management conviction in the company's near-term prospects. In stark contrast, significant bearish signals emerge from high-level executives at Sea Ltd (COO sold $1.38M) and Keysight Technologies (SVP sold $652K), both executed via 10b5-1 plans, indicating pre-planned but notable portfolio diversification. The filing set also reveals major equity awards at ASE Technology Holding Co. (1.875M shares granted to 8 executives), a tax withholding sale at Innovex International ($152K), and a planned sale by a LA-Z-BOY director ($116K). While numerous filings are of low individual materiality, the aggregate pattern across TSMC is a standout positive cluster, while sales at Sea Ltd and Keysight warrant closer monitoring.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 09, 2026

The September 9, 2026 filing set reveals a pronounced acceleration in SPAC activity, with three distinct transactions—two new business combination announcements (Daedalus/HubX, Unite/Blue Laser Fusion) and one extension vote (Alchemy)—highlighting a market still actively seeking and completing de-SPAC deals. The successful tender offer and short-form merger of Selectis Health by Black Pearl Equities at $5.75/share (90.93% tendered) demonstrates a clean, fully-cashed-out acquisition, while Barinthus Biotherapeutics' scheme of arrangement marks a completed cross-border take-private with a stock-for-stock exchange. Notably, no filing disclosed specific financial metrics (revenue, margins, or period-over-period comparisons), indicating a data-scarce environment where qualitative signals—such as Point72's $75M investment commitment in HubX and the unqualified audit opinion for Blue Laser Fusion—carry outsized weight. The extension votes (Alchemy to Sept 2027, Andretti to 36 months from IPO) reflect a broader trend of SPACs buying time to secure quality targets, reducing liquidation risk but extending capital lock-up periods. Overall, the digest points to a bifurcated market: high-quality targets attracting institutional backing (HubX, Blue Laser Fusion) versus cash-strapped SPACs (Alchemy, Andretti) relying on extensions to avoid returning capital. Investors should focus on the execution risk of pending deals and the strategic rationale behind take-privates, as financial disclosures remain limited.

6 high priority 6 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 09, 2026

The overnight filing cycle from September 8-9, 2026, reveals a market dominated by significant insider selling, particularly concentrated in the technology sector, where Silver Lake entities executed a coordinated, multi-faceted sell-down of Dell Technologies Inc. shares totaling over $36 million across multiple filings. This aggressive disposition by a major director, combined with substantial sales at Cloudflare and Sandisk, signals potential sector rotation or profit-taking by sophisticated investors. Conversely, a notable insider buy at Enovis Corp and a director purchase at ASTROTECH Corp provide isolated bullish signals. The period also features transformative corporate actions, including the full acquisition of Selectis Health at a 90.93% tender success rate and the proposed de-SPAC merger of General Fusion with Spring Valley Acquisition Corp. III, alongside a high-risk delisting notice for Premium Catering. Financially, ASE Technology Holding Co., Ltd. reported exceptional growth with revenues surging 45.7% YoY, while VolitionRx faces severe dilution risks from covenant breaches and down-round adjustments. The overall sentiment is cautious, with a clear theme of cash extraction by insiders and a focus on capital returns through buybacks at Novo Nordisk and KT Corp.

35 high priority 15 medium 50 total filings
· daily

Biotech Small-Cap Approvals — September 08, 2026

During the week of September 8, 2026, the FDA approved five products, with a mix heavily skewed toward biosimilar entries (4 approvals) and one high-conviction NME. The dominant therapeutic theme is absent as approvals span diverse mechanisms (neurology, bone health, psychiatry, cardiovascular). The highest-conviction signal is the NME approval of ZILGANERSEN (IONIS PHARMS INC) for an undisclosed indication, granted Priority Review, representing a significant commercial catalyst for Ionis and validating its antisense platform. Key risks include the competitive pressure from four biosimilar approvals—RELUGOLIX (SANDOZ INC), ALENDRONATE SODIUM (PRECISION DOSE INC), PIMAVANSERIN (TEVA PHARMS USA), and SACUBITRIL (AUROBINDO PHARMA LTD)—which will erode originator revenues in their respective markets. Investors should watch for launch dynamics and payer coverage decisions for ZILGANERSEN, as well as the pace of biosimilar uptake for the other four agents.

5 total filings
· daily

NME Blockbuster Approvals — September 08, 2026

During the period of September 08, 2026, the FDA approved one NME, ZILGANERSEN (ZANVASTRO) from IONIS PHARMS INC, which received Priority Review, signaling a strong unmet need and a bullish investment signal. The approval mix was 0 NMEs, 0 biosimilars, and 0 label expansions, with 1 'Other' approval type (likely a fallback classification). The dominant therapeutic area theme is not clearly defined due to the single approval, but the Priority Review designation underscores the potential commercial significance. The highest-conviction signal is the approval of ZILGANERSEN, which could represent a new revenue stream for Ionis, though commercial details remain undisclosed. Key watch items include the lack of disclosed peak sales, exclusivity, and pricing data, which are critical for assessing market potential.

1 total filings
· daily

New Drug Approvals (Original) — September 08, 2026

During the period of September 08, 2026, the FDA issued five original approvals, all classified as 'Other' with no NMEs, biosimilars, or label expansions formally identified. The highest-conviction signal is the bullish NME approval of ZILGANERSEN (ZANVASTRO) by Ionis Pharmaceuticals, which received Priority Review and represents a significant commercial opportunity for the sponsor. The remaining four approvals—RELUGOLIX (Sandoz), ALENDRONATE SODIUM (Precision Dose), PIMAVANSERIN (Teva), and SACUBITRIL (Aurobindo)—are neutral signals, likely representing generic or biosimilar entries that could introduce competitive pressures in their respective markets. Key watch items include the commercial execution of ZILGANERSEN and the potential market impact of the multiple 'Other' approvals. No dominant therapeutic area theme emerges, though the mix of approvals suggests a steady regulatory cadence across diverse drug classes.

5 total filings
· daily

New Federal Contractors — September 08, 2026

This digest covers a single $210.2 million civilian sector contract awarded to North Wind Portage, Inc. by the Department of Energy (DOE) for environmental remediation at the Moab and Crescent Junction sites. The contract is not defense-related, marking a pure civilian signal with a neutral sentiment (strength 5/10). As a firm-fixed-price delivery order under a small business set-aside, execution risk is elevated despite DOE’s robust long-term cleanup mandate. The highest-conviction signal is the partial outlay of $66.5 million (32% completion), suggesting either slower-than-expected progress or efficient cost management, but no bullish or bearish extremes are present. Key risk is the fixed-price structure for high-cost radioactive material handling; watch for option exercises beyond the original 2022 performance end date.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 08, 2026

The sole contract in this digest is a $210.2 million firm-fixed-price delivery order awarded to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian agency award (0/1 defense-related), reflecting continued DOE investment in legacy site cleanup. The contract, awarded in 2016 with performance through March 2022, shows only $66.5 million outlayed (about 32% completion), indicating potential execution delays or slow spend. The highest-conviction signal is the neutral outlook for North Wind Portage given the fixed-price structure and small business designation, which introduces execution risk but also potential efficiency upside. Key watch items include contract extension or option exercise beyond March 2022 and DOE budget allocations for environmental management, which will determine follow-on opportunities.

1 total filings
· daily

Contract Deobligations Alert — September 08, 2026

The sole contract in this period is a $210.2 million firm-fixed-price delivery order from the Department of Energy (DOE) to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian contract (0/1 defense-related), reflecting ongoing DOE environmental management spending on legacy site cleanup. The contract, awarded in 2016 with performance through March 2022, shows $66.5 million outlayed (~32% completion), indicating partial execution and potential for follow-on work. The highest-conviction signal is the stable, long-term nature of DOE environmental remediation, though the fixed-price structure and small business designation introduce execution risk and limited scalability. Key watch items include potential contract extensions beyond March 2022 and DOE budget allocations for environmental management.

1 total filings
· daily

Contract Option Exercises — September 08, 2026

This digest covers a single $210.2 million contract option exercise from the Department of Energy (DOE) to North Wind Portage, Inc., a small business joint venture with Leidos. The contract is entirely civilian, with zero defense-related awards, reinforcing a stable but low-growth theme in DOE environmental remediation. The highest-conviction signal is neutral: the firm-fixed-price structure and 32% completion rate suggest manageable execution risk but limited upside for investors. A key risk is the contract's original performance period ending in March 2022, implying potential delays or extensions that could signal cost overruns or budget reallocations.

1 total filings
· daily

All DOE Contracts — September 08, 2026

The single Department of Energy (DOE) contract analyzed for September 8, 2026, totaling $210.2 million, underscores a civilian-sector environmental remediation theme with zero defense exposure. The award to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, is a firm-fixed-price delivery order for Moab and Crescent Junction site cleanup, with only $66.5 million outlayed (32% completion) as of the data snapshot. The highest-conviction signal is neutral, reflecting stable DOE environmental management spending but tempered by execution risk from the fixed-price structure and limited scalability due to the small business designation. A key risk is the contract's 2022 performance end date, leaving investors to monitor whether options were exercised or follow-on awards materialized.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 08, 2026

The sole contract in this digest is a $210.2 million firm-fixed-price delivery order awarded to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites in Utah. This is a civilian award (0/1 defense-related), reflecting ongoing DOE environmental management spending on legacy site cleanup. The contract, awarded in 2016 with a performance period through March 2022, has $66.5 million outlayed, indicating about 32% completion. The highest-conviction signal is the stable, long-term nature of DOE environmental management, but the firm-fixed-price structure and small business designation introduce execution risk and limited scalability. Key watch items include potential contract extensions or option exercises and DOE budget allocations for environmental management.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 08, 2026

The sole contract in this period is a $210.2 million firm-fixed-price delivery order from the Department of Energy to North Wind Portage, Inc., a small business joint venture under North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites. With zero defense-related awards, the digest is entirely civilian, reflecting ongoing DOE environmental management spending. The highest-conviction signal is neutral: the award signals stable but low-tech remediation demand, but the fixed-price structure and partial completion (32%) introduce execution risk for a small business. Key watch items include whether options were exercised beyond the March 2022 performance end and DOE budget trends for legacy site cleanup.

1 total filings
· daily

DOE Energy Grants — September 08, 2026

The digest covers a single $210.2 million civilian contract from the Department of Energy to North Wind Portage, Inc., a small business under the North Wind-Leidos JV LLC, for environmental remediation at the Moab and Crescent Junction sites. This award is entirely civilian (0/1 defense-related) and reflects ongoing DOE environmental management spending, a stable but low-growth sector. The highest-conviction signal is neutral, given the firm-fixed-price structure that introduces execution risk and the partial completion status (32% outlayed). A key risk is the contract's 2022 expiration, with no clear indication of follow-on awards, which could signal a gap in revenue for the contractor.

1 total filings
· daily

General Federal Contracts — September 08, 2026

This digest covers a single $210.2 million civilian contract awarded to North Wind Portage, Inc. by the Department of Energy for environmental remediation at the Moab and Crescent Junction sites. The contract is fully civilian, with no defense-related awards, and the aggregate signal strength is neutral at 5.0/10. The highest-conviction signal is the fixed-price structure, which introduces execution risk for the small business contractor, while the partial outlay of $66.5 million suggests about 32% completion. Key risks include potential cost overruns under the firm-fixed-price terms and the uncertainty of follow-on contracts beyond the original March 2022 performance period.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — September 08, 2026

The 25 filings for the S&P 500 Technology sector reveal a period of significant strategic realignment and capital deployment, with insider activity providing mixed signals. The most critical development is Qualcomm's strategic warrant issuance to an Amazon affiliate, unlocking a potential $60 billion server chip collaboration that reshapes the semiconductor landscape. Adobe's leadership transition marks a new era, with a clear succession plan that could drive renewed focus on AI and customer experience. Insider selling at Datadog and NVIDIA, particularly the $55M sale by NVIDIA Director Mark Stevens, raises caution flags on valuation, while routine director awards at Microsoft and Accenture indicate stable governance. The dominant theme is the massive capital flow into AI and cloud infrastructure, with Qualcomm's deal being the most tangible example. The lack of financial performance data in most filings limits period-over-period trend analysis, but the strategic moves point to a sector aggressively positioning for the next growth cycle.

13 high priority 12 medium 25 total filings
· daily

Nasdaq 100 Stocks SEC Filings — September 08, 2026

The 21 filings for the NASDAQ-100 stream are dominated by routine director equity awards at Microsoft, which are non-events for investors. The most significant developments are the CEO transition at Adobe, a major strategic collaboration between Qualcomm and Amazon, and continued capital allocation at Strategy Inc. Insider selling activity is notable at NVIDIA, Meta, and PayPal, though mostly under 10b5-1 plans. The Qualcomm-Amazon deal is the standout opportunity, potentially worth up to $60 billion, while Adobe's leadership change signals a strategic shift. Strategy's pause in bitcoin purchases and preferred share repurchases indicate a focus on balance sheet management. Overall, the stream shows a mix of routine administrative filings and a few high-impact strategic announcements.

5 high priority 16 medium 21 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — September 08, 2026

The September 8, 2026, batch of 50 SEC filings reveals a period of significant portfolio repositioning by major institutional investors, particularly FMR LLC (Fidelity), which executed a series of complete exits and new passive stakes. The most critical development is an escalating activist campaign at Braemar Hotels & Resorts, where the largest shareholder is nominating a full slate of directors, signaling a potential boardroom battle. A notable sector theme is the concentrated institutional ownership in Calamos closed-end funds, with MetLife holding dominant positions in several preferred share series. While most filings are routine passive disclosures, the combination of Fidelity's exits from Leggett & Platt and Orla Mining, alongside new 10%+ stakes in companies like Viatris and Graphic Packaging, suggests a strategic rotation away from certain sectors. The data also highlights a multi-class share structure concern at NaaS Technology, where a single entity controls 57.7% of voting power despite owning 51.9% of equity, creating a significant governance risk for minority shareholders.

7 high priority 43 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — September 08, 2026

The five filings, all from S&P 500 Financials (insurance) companies, are dominated by insider transactions, with a notable mix of routine equity awards and a significant sale by a 10% owner. Allstate shows a pattern of equity compensation and tax withholding, while AIG's Chief Underwriting Officer received a substantial stock award. The most material event is AFLAC's 10% owner, Japan Post Holdings, selling shares under a 10b5-1 plan, signaling potential long-term de-risking. No period-over-period financial comparisons or forward-looking guidance were provided, limiting trend analysis. Overall, the filings suggest normal insider activity, with the AFLAC sale being the key watch item for sentiment.

5 high priority 5 total filings
· daily

S&P 500 Energy Sector SEC Filings — September 08, 2026

The three filings in this digest are all Form 4 insider transaction reports from S&P 500 Energy constituents, indicating a day of routine insider activity rather than major corporate events. The most notable signal is a small purchase by a 10% owner at Texas Pacific Land Corp, which, while minimal in size, suggests continued confidence from a major shareholder. Targa Resources and Baker Hughes both reported insider transactions—a gift and tax-related dispositions, respectively—which are typically non-directional and carry low informational value. No period-over-period financial trends, forward-looking guidance, or capital allocation changes were disclosed in these filings, limiting the ability to identify broader sector themes. The overall sentiment across the filings is neutral to positive, with no high-risk flags or significant catalysts. Investors should view these as routine compliance filings, with the Texas Pacific Land purchase as the only mildly bullish signal.

3 high priority 3 total filings